Xceed reports positive data from sheep trial

By Elaine Rigoli

Tampa, Fla., Sept. 5 - Xceed Biotechnology Ltd. said Tuesday that its 60% subsidiary, PolyNovo, has released positive preliminary results from a long-term study evaluating NovoSorb in bone.

The results suggest that implementation of NovoSorb in preformed and injectable formulations in sheep is consistent with current human surgical practice for similar non-biodegradable products.

Xceed is a biotechnology company based in Melbourne, Australia.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.